



Particulars	Quarter Ended 30.09.2012
<b>B. INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	Nil
Received during the quarter	18
Disposed of during the quarter	18
Remaining unresolved at the end of the quarter	Nil

Notes:

- The Company is essentially in the pharmaceutical business segment.
- In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High Courts wherein it was held in favour of the Company. The orders were challenged before the Hon'ble Supreme Court by the Government. The Hon'ble Supreme Court by a separate order restored the matter to the jurisdictional High Court for interpreting the Drug Policy on the basis of directions and principles laid down by them and also restrained the Government from taking any coercive action against the Company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand aggregating to ₹1654.92 crore (inclusive of principal amount for the period July 1995 to April 2009 and interest upto January 2012).
- The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.
- \*Tax expense is inclusive of current tax and deferred tax.
- The Statement of Assets and Liabilities is as under:

Particulars	(₹ in crores)	
	As At 30.09.2012	As At 31.03.2012
	Unaudited	Audited
<b>A. EQUITY AND LIABILITIES</b>		
<b>1. Shareholders' fund</b>		
(a) Share capital	160.58	160.58
(b) Reserves and surplus	8290.47	7389.70
<b>Shareholders' fund</b>	<b>8451.05</b>	<b>7550.28</b>
<b>2. Non-current liabilities</b>		
(a) Long-term borrowings	2.20	2.20
(b) Deferred tax liabilities (net)	247.45	232.45
(c) Long-term provisions	39.74	29.12
<b>Non-current liabilities</b>	<b>289.39</b>	<b>263.77</b>
<b>3. Current liabilities</b>		
(a) Short-term borrowings	15.34	10.00
(b) Trade payables	673.93	600.39
(c) Other current liabilities	392.61	357.94
(d) Short-term provisions	40.39	211.41
<b>Current liabilities</b>	<b>1122.27</b>	<b>1179.74</b>
<b>Total</b>	<b>9862.71</b>	<b>8993.79</b>
<b>B. ASSETS</b>		
<b>1. Non-current assets</b>		
(a) Fixed assets	2974.17	3002.66
(b) Capital Work-in-Progress	363.70	343.45
(c) Non-current investments	461.83	461.83
(d) Long-term loans and advances	359.14	385.65
(e) Other non-current assets	0.24	0.24
<b>Non-current assets</b>	<b>4159.08</b>	<b>4193.83</b>
<b>2. Current assets</b>		
(a) Current investments	1404.50	573.22
(b) Inventories	1857.51	1824.50
(c) Trade receivables	1685.21	1519.31
(d) Cash and cash equivalents	91.29	55.06
(e) Short-term loans and advances	647.32	773.79
(f) Other current assets	17.80	53.98
<b>Current assets</b>	<b>5703.63</b>	<b>4799.66</b>
<b>Total</b>	<b>9862.71</b>	<b>8993.79</b>

- The results for the quarter ended 30<sup>th</sup> September, 2012 have been subjected to Limited Review by the Statutory Auditors, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 5<sup>th</sup> November, 2012.

By order of the Board  
For **CIPLA LIMITED**

Mumbai  
5<sup>th</sup> November, 2012

**Dr. Y. K. Hamied**  
Chairman & Managing Director

**Financial Review – Period ended Sep 2012**

(₹ in crores)

	Quarter Ended			Half Year Ended		
	30/09/2012	30/09/2011	% change	30/09/2012	30/09/2011	% change
Domestic	961.67	847.03	13.5%	1931.34	1590.65	21.4%
Exports -						
Formulations	1038.93	751.58	38.2%	1849.04	1410.45	31.1%
APIs & others	173.77	159.48	9.0%	342.23	330.8	3.5%
<b>Total Exports</b>	<b>1212.70</b>	<b>911.06</b>	<b>33.1%</b>	<b>2191.27</b>	<b>1741.25</b>	<b>25.8%</b>
% of exports to total sales	55.8%	51.8%		53.2%	52.3%	
<b>Total Sales</b>	<b>2174.37</b>	<b>1758.09</b>	<b>23.7%</b>	<b>4122.61</b>	<b>3331.90</b>	<b>23.7%</b>
Other operating income						
Technology knowhow/fees	4.64	7.77		10.39	17.60	
Others	41.33	30.06		76.39	52.65	
<b>Total</b>	<b>45.97</b>	<b>37.83</b>	<b>21.5%</b>	<b>86.78</b>	<b>70.25</b>	<b>23.5%</b>
<b>Income from Operations</b>	<b>2220.34</b>	<b>1795.92</b>	<b>23.6%</b>	<b>4209.39</b>	<b>3402.15</b>	<b>23.7%</b>
<b>Material Cost</b>	788.60	711.65		1521.02	1379.88	
% to total sales	36.3%	40.5%		36.9%	41.4%	
<b>Operating margin</b>	676.95	429.25	57.7%	1216.80	790.12	54.0%
% to income from operations	30.5%	23.9%		28.9%	23.2%	
<b>Profit before tax</b>	661.77	393.92	68.0%	1180.77	713.81	65.4%
% to income from operations	29.8%	21.9%		28.1%	21.0%	
<b>Profit after tax</b>	500.01	308.97	61.8%	900.77	562.31	60.2%
% to income from operations	22.5%	17.2%		21.4%	16.5%	

During the quarter, the company posted a growth of about 24% in income from operations. Domestic sales grew by more than 13% and export sales grew by more than 33%. Operating margins and profits after tax have increased by about 58% and 62% respectively on a year-on-year basis.

Material cost has decreased by 4% mainly on account of changes in product mix viz. lower proportion of anti-retrovirals and higher contribution of anti-depressant segment (Escitalopram) coupled with increased realizations. As a result, operating margins have also increased by more than 6%.

The increase in staff cost of Rs. 55 cr is due to annual increments and increase in manpower. Other expenditure has increased by Rs. 42 cr for the quarter mainly on account of increase in travel expenses, marketing expenditure, professional charges, etc. Tax for the current quarter has increased due to higher profits.